SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer
This post hoc pooled analysis reports a long-term comparison of SBRT and HDR-BT using prospective data. SBRT had significantly lower BCF and acute genitourinary AEs, and there was no significant difference in late PR-QoL.
Authors
- Gerard Morton (ORCID: https://orcid.org/0000-0002-4903-1233)
- Cristian Udovicich (ORCID: https://orcid.org/0000-0001-6093-5164)
- M Mcguffin
- Meghan Kulasingham-Poon
- Melanie Davidson (ORCID: https://orcid.org/0000-0002-0587-6840)
- Jay Detsky (ORCID: https://orcid.org/0000-0002-0117-6839)
- S. Liu
- Thomas Kennedy (ORCID: https://orcid.org/0000-0002-1603-8121)
- William Chu (ORCID: https://orcid.org/0000-0002-9307-0184)
- Liu G
- Ananth Kumar Ravi
- Alexandre Mamedov
- Wee Loon Ong
- Andrea Deabreu
- Andrew Loblaw
- Patrick Cheung
- Hans Chung
- John M. Hudson
- Chia-Lin Tseng
- Liying Zhang
- Joelle Helou
Institutions
- Western University (CA)
- Sunnybrook Health Science Centre (CA)
- University of Toronto (CA)
- Genesis HealthCare (US)
- Kelowna General Hospital (CA)
- Health Sciences Centre (CA)
- Alfred Health (AU)
- Monash University (AU)
- Okanagan University College (CA)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2026-02-25
- DOI
- https://doi.org/10.1001/jamanetworkopen.2026.0146
- Citations
- 1
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 36.44